AACE Seventeenth Annual Meeting & Clinical Congress

Walt Disney World Dolphin Resort
Southern Hemisphere II

Saturday, May 17, 2008
Breakfast: 5:45 AM
Educational Session: 6:15–7:45 AM


Diabetic nephropathy is a common microvascular complication that accounts for a substantial portion of diabetes-related morbidity and mortality. Hyperglycemia has been implicated as a causal factor in the development of microvascular diabetic complications; and evidence underscores the need for strict glycemic control in both primary and secondary prevention of diabetic nephropathy. Glycemic Control for the Kidney, by the Kidney: Exploring the Role of SGLT2 Inhibition in Type 2 Diabetes Mellitus is a live, 90-minute CME activity designed to meet the educational needs of clinicians involved in the care of patients with type 2 diabetes. The symposium features a panel of expert faculty, representing the specialties of endocrinology and nephrology. The activity encompasses a scientific update on the role of hyperglycemia in nephropathy, as well as detailed discussions of the rationale and available data regarding the use of a novel oral hypoglycemic therapy that interferes with renal glucose reabsorption via selective inhibition of the sodium-glucose transporter-2 (SGLT2). Following the presentations, attendees will have the opportunity to participate in a question and answer session.


This activity is designed for physicians with special education, training, and interest in the practice of clinical endocrinology.


Upon completion of this course, the participants should be able to:
• Describe the role of hyperglycemia in the development and progression of diabetic nephropathy
• Explain how an SGLT2 inhibitor acts to reduce blood glucose and what its clinical role may be in the treatment of T2DM
• Summarize the evidence from observational, preclinical, and clinical trials regarding the efficacy and safety of SGLT2 inhibition


The American Association of Clinical Endocrinologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Association of Clinical Endocrinologists designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

To download and save the PDF files to your desktop, please "right click" on the thumbnails and select "Save Target As..."